1. UNCY faces a class action lawsuit by investors. 2. Allegations include misleading statements about FDA compliance. 3. Class period for claims is March 29, 2024, to June 27, 2025. 4. Investors can register for updates and lead plaintiff appointment. 5. Deadline for lead plaintiff registration is October 14, 2025.
The allegations of misleading statements could diminish investor confidence. Historical instances show stocks often decline during similar legal troubles.
The lawsuit indicates significant legal risks for UNCY, affecting share value. Legal troubles raise concerns among stakeholders and potential investors.
The ongoing litigation may adversely affect stock performance over time. Legal battles can extend and influence investor sentiment and stock viability.
NEW YORK, Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ:UNCY).
Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
CLASS PERIOD: March 29, 2024 to June 27, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application's regulatory prospects were likewise overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.
DEADLINE: October 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/unicycive-therapeutics-inc-loss-submission-form/?id=165513&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of UNCY during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 14, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/uncy-lawsuit-alert-the-gross-law-firm-notifies-unicycive-therapeutics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302548499.html
SOURCE The Gross Law Firm